TYPHERIX is a clear colourless liquid containing the cell surface Vi polysaccharide extracted from Salmonella typhi Ty2 strain. Typherix is indicated for active immunization against typhoid fever in persons two years of age and older. Protection is not conferred against paratyphoid fever or illness caused by non-invasive Salmonellae.
One dose administered intramuscularly ensures protection for at least 3 years. The vaccine must be given at least 2 weeks prior to travel to endemic areas. A single dose of 0.5 mL containing 25 μg of the Vi polysaccharide of Salmonella typhi is recommended. For adults 19 years and older TYPHERIX can be co-administered with HAVRIX 1440 in opposite arms. For other injectable vaccines, different syringes and different injection sites must be used. Booster Dose for individuals who remain at risk, or who may be re-exposed to risk of typhoid fever, it is recommended that they be revaccinated using a single dose of vaccine every 3 years.
For latest IAP updates see revised immunization schedule.
TYPHERIX should not be administered to subjects with known hypersensitivity to any component of the vaccine or to subjects having shown signs of hypersensitivity after previous administration. The administration of TYPHERIX should be postponed in subjects suffering from acute severe febrile illness.